2026-04-17T14:48:10Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4551322025-07-29T18:48:42Zcom_2072_98col_2072_378192

A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients Elez, Elena Pericay, Carles Valladares-Ayerbes, Manuel Bando, Inmaculada Safont, Maria Jose Gallego, Javier Grávalos, Cristina Arrivi, Antonio Carrato, Alfredo Conde, Verónica Ortiz, Maria José López, Carlos Alonso, Beatriz Ruiz de Mena, Inmaculada Díaz-Rubio, Eduardo Tabernero, Josep Aranda Aguilar, Enrique Universitat Autònoma de Barcelona Colorectal cancer Oncology Targeted agents are standard treatment for RAS wild-type metastatic colorectal cancer in the first- and second-line settings. This phase 2 study determined the benefit of targeting the epidermal growth factor receptor (EGFR) with panitumumab plus irinotecan in irinotecan-refractory patients. KRAS exon-2 wild-type patients failing prior irinotecan received panitumumab (6 mg/kg) and irinotecan (180 mg/m²) every 2 weeks. The primary endpoint was the overall response rate (ORR). Secondary endpoints included safety, progression-free survival (PFS) and overall survival (OS). KRAS exon-2 status was evaluated centrally, along with NRAS, BRAF mutations, epiregulin, amphiregulin, PTEN and EGFR copy number status, and correlated with efficacy. Sixty-one patients were treated. Among the 46 wild-type RAS patients, the ORR was 15.2% (seven partial responses), with median PFS of 3.8 months (95% CI 2.7-4.3) and median OS of 12.5 months (95% CI 6.7-15.9). Wild-type BRAF patients showed a 13.0% response rate. No significant correlations between response and baseline biomarker expression were identified. Common grade 3-4 adverse events were diarrhoea and rash (18.0% each), hypomagnesaemia and asthenia (8.2% each). The addition of panitumumab to irinotecan as salvage therapy is feasible but has limited activity in irinotecan-refractory metastatic colorectal cancer. No biomarkers predictive of response were identified. 2019 Article https://ddd.uab.cat/record/226563 urn:10.1038/s41416-019-0537-z urn:oai:ddd.uab.cat:226563 urn:pmid:31363167 urn:pmcid:PMC6738054 urn:pmc-uid:6738054 urn:articleid:15321827v121p378 urn:scopus_id:85069908143 urn:oai:pubmedcentral.nih.gov:6738054 urn:oai:egreta.uab.cat:publications/d711d593-3cbd-4c74-ae99-a8f3d6e4ee92 eng British journal of cancer ; Vol. 121 (july 2019), p. 378-383 open access Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. https://creativecommons.org/licenses/by/4.0/ application/pdf